IGF1R and familial pancreatic carcinoma: Interestingly, with the exception of PT-45, the combination of the IGF-IR inhibitor NVP-AEW541 with afatinib was superior to that of NVP-AEW541 with gemcitabine leading to synergistic growth inhibition of all pancreatic cancer cell lines (Table 2, Figure 4).